Drug Profile
Rabies DNA vaccine - LigoCyte/NIAID
Latest Information Update: 05 Aug 2004
Price :
$50
*
At a glance
- Originator LigoCyte Pharmaceuticals; National Institute of Allergy and Infectious Diseases
- Class Gene therapies; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Rabies
Most Recent Events
- 05 Aug 2004 Discontinued - Preclinical for Rabies in USA (IM)
- 12 Jan 2004 No development reported - Preclinical for Rabies in USA (IM)
- 05 Oct 2001 LigoCyte has entered into a CRADA with the NIAID for development of the rabies vaccine